ABBV: Bull Flag detected on 1 Sep 2026

ABBV is forming a bull flag following a weak rounding bottom established in December 2025. The current price of $256.42 sits 4.13% below the 52-week high and 35.38% above the 52-week low, indicating mid-range positioning. The pattern shows solid structure (12.4/15), breakout (12.4/13), and volume (12.0/12) scores, yielding an overall quality of 68.8 points. The stock is confined between support at 241.2 and resistance at 267.47. RSI at 51.74 shows neutral momentum, while MACD remains slightly negative (-0.3349), suggesting the consolidation retains upside potential without excessive overbought conditions.

AbbVie reported full-year 2025 net revenues of $61.160 billion, an increase of 8.6%, with immunology portfolio revenues of $30.406 billion (+14.0%), driven by Skyrizi at $17.562 billion and Rinvoq at $8.304 billion. In Q2 2026, the company posted EPS of $3.65, missing analyst expectations of $3.77, though mid-year revenues reached $31.992 billion for the first half, up 11% year-over-year. AbbVie announced a proposed acquisition of Apogee Therapeutics for approximately $10.9 billion to strengthen immunology leadership. Recent pipeline progress includes an FDA submission for Skyrizi in Crohn's disease, with approval expected later this year. The company faces significant legacy blockbuster erosion, with Humira revenues down 37%, necessitating dependence on newer immunology franchises.

A successful breakout above 267.47 would target the conservative measure move of 264.88, with the win_probability of 73.21% indicating solid historical success rate for this setup. Volume confirmation is critical—the current volume ratio of 0.93 is slightly below the 20-day average of 4.625M shares, so a breakout on elevated volume would strengthen conviction. The invalidation level sits at key support of 241.2; a close below this price would signal pattern failure and warrant reassessment. The low beta of 0.37 suggests ABBV will move less violently than the broader market, making this a relatively stable setup.

Next earnings are scheduled for October 23, 2026, providing a near-term catalyst that could disrupt the pattern consolidation. The recent Q2 earnings miss despite strong revenue growth raises profitability concerns and may have contributed to the stock's -3.06% decline over the past week. Volume is currently 7% below average, weakening conviction in the consolidation phase. Humira's steep 37% revenue decline represents structural headwind requiring offset from newer products. The macd_histogram at -0.3349 remains negative despite bullish pattern context, suggesting momentum divergence risk. With low volatility (atr_pct of 2.1%), sharp adverse moves could be more impactful proportionally. Regulatory risk exists around pending FDA decisions for new indications.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.